Researchers identify key regulators of urinary concentration in the kidney

Proper function of the kidney is critical for concentrating urine, regulating blood pressure, and for the tight control of electrolyte levels in the blood. The kidney achieves these important functions through many microscopic functional units, called nephrons. These nephrons consist of different segments with distinct functions. How these segments form during development and how their function is maintained in the […]

Racial disparities in kidney transplantation access are highest among young adults

In a retrospective study of adults initiating kidney failure treatment during 2011-2018, disparities in kidney transplantation by race were highest among patients age 22-44 years of age. Within this age group, kidney failure was treated by kidney transplantation among 10.9% of White patients but only 1.8% of Black and 4.4% of Hispanic patients. Research has shown wide racial/ethnic disparities in use […]

Alternative to using race in kidney function test found

Kaiser Permanente study supports eventual use of new way to estimate kidney function. Researchers have identified an approach to remove race from equations used to estimate a person’s kidney function. These equations have been criticized for potentially perpetuating racial health disparities. The findings, reported September 23 in the New England Journal of Medicine, are expected to inform National Kidney Foundation–American Society […]

GSK announces positive headline results from five phase III studies of daprodustat for patients with anaemia due to chronic kidney disease

GlaxoSmithKline plc announced positive headline results from five studies of the Phase III ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for patients with anaemia due to chronic kidney disease (CKD). The ASCEND programme showed that daprodustat met its primary efficacy endpoint in each study, demonstrating an improvement in […]

Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation

Hansa Biopharma, announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported in an article, which has been accepted for publication in the American Journal of Transplantation, 84% of patients still had a functioning allograft after three years, three allograft losses occurred during the first six months with two further losses occurring between […]